Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.
Other pathogens responsible for the disease include Legionella pneumophila, Coxiella burnetii, and Chlamydia psittaci, each associated with distinct environmental or zoonotic exposures.
Mechanisms of Pathogenesis and Host Interaction
Mycoplasma pneumoniae establishes infection by adhering to the ciliated epithelial cells lining the respiratory tract. This attachment is mediated by a specialized surface protein known as P1 adhesin, which binds to sialoglycoprotein receptors located at the base of the host’s cilia. The binding not only secures the bacterium in place but also initiates a cascade of pathogenic events. Specifically, the attachment impairs ciliary motion—a critical defense mechanism responsible for clearing airway secretions and inhaled particles. This immobilization leads to mucus retention and the accumulation of particulate matter within the airway lumen.
Cellular Damage and Immune Response
The bacterium further compromises respiratory function by releasing cytotoxic substances, including hydrogen peroxide, other reactive oxygen species, and proteolytic enzymes. These molecules damage epithelial cells, induce cell death, and promote irritation and inflammation of surrounding tissues. The resulting environment—rich in mucus and cellular debris—facilitates bacterial persistence and increases the risk of secondary infections.
Clinical Features and Diagnosis
Clinically, atypical pneumonia caused by M. pneumoniae typically presents after an incubation period of 1–4 weeks with symptoms such as sore throat, persistent dry cough, and low-grade fever. In some cases, M. pneumoniae may also cause extrapulmonary manifestations, including rash, hemolytic anemia, and neurological complications like encephalitis. The progression is generally milder than that of typical bacterial pneumonia and often does not necessitate bed rest, earning it the colloquial name “walking pneumonia,” which reflects its minimal impact on daily activity.
Diagnosis typically involves a combination of clinical evaluation, imaging (such as chest X-rays showing diffuse interstitial infiltrates), and laboratory testing. Polymerase chain reaction (PCR) assays and serological tests for M. pneumoniae-specific antibodies are commonly used for confirmation.
Treatment and Considerations
Because M. pneumoniae lacks a cell wall, it is inherently resistant to beta-lactam antibiotics. Treatment requires antibiotics that target intracellular pathogens, such as macrolides, tetracyclines, or fluoroquinolones. Awareness of these microbial features is essential for effective treatment and responsible antibiotic use.
Atypical pneumonia in humans is most often caused by Mycoplasma pneumoniae.
It spreads mainly through respiratory droplets.
M. pneumoniae initiates infection in the respiratory tract by attaching to the apical surface of the ciliated epithelial cells.
It uses a specialized surface protein called P1 adhesin to bind to glycoprotein receptors on the epithelial cells.
Once attached, the bacteria halt ciliary movement of epithelial cells. This prevents clearance of mucus and traps inhaled particles in the airways.
The bacteria also release virulence factors, such as the CARDS toxin, which damage epithelial cells and lead to cell death.
The accumulation of mucus and cellular debris results in airway inflammation.
This environment supports further growth of M. pneumoniae and may enable secondary infections.
Clinically, atypical pneumonia presents with a persistent dry cough, sore throat, and low-grade fever.
繁體中文
